Legend Biotech Corporation
As of Oct 22, 2026, Legend Biotech is in Stage 4, the downtrend phase, now in week 8 (since Aug 31, 2026). It closed at $18.90, 47.9% below its 52-week high and below its 200-day average, which is falling.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other ind… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LEGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LEGN among Biotechnology328th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …328 | LEGN | Stage 4 · wk 8 | 27 | +2.4% |
Legend Biotech: quick answers
What stage is Legend Biotech in?
As of Oct 22, 2026, Legend Biotech (LEGN) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 31, 2026 and is in week 8. What the four stages mean
Is Legend Biotech in an uptrend?
No. Legend Biotech is in a Stage 4 downtrend. It trades 14.8% below its 200-day average, which is falling.
How far is Legend Biotech from its 52-week high?
Legend Biotech closed at $18.90 on Oct 22, 2026, 47.9% below its 52-week high of $36.28. Its 52-week low is $16.65.
How has Legend Biotech performed over the past year?
As of Oct 22, 2026, Legend Biotech is down 42.5% over the past year and down 12.1% so far in 2026.
Which sector and industry is Legend Biotech in?
Legend Biotech is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.